Burkett Asset Management Ltd Acquires New Stake in Novo Nordisk A/S $NVO

Burkett Asset Management Ltd purchased a new position in shares of Novo Nordisk A/S (NYSE:NVO) in the fourth quarter, HoldingsChannel.com reports. The firm purchased 35,835 shares of the company’s stock, valued at approximately $1,823,000. Novo Nordisk A/S comprises 1.8% of Burkett Asset Management Ltd’s portfolio, making the stock its 17th biggest holding.

A number of other large investors have also recently bought and sold shares of NVO. Godfrey Financial Associates Inc. acquired a new stake in Novo Nordisk A/S during the 4th quarter worth about $25,000. WealthCollab LLC grew its holdings in Novo Nordisk A/S by 93.5% during the 4th quarter. WealthCollab LLC now owns 538 shares of the company’s stock worth $27,000 after acquiring an additional 260 shares during the period. American National Bank & Trust acquired a new stake in Novo Nordisk A/S during the 4th quarter worth about $28,000. Maseco LLP acquired a new stake in Novo Nordisk A/S during the 4th quarter worth about $29,000. Finally, Jackson Grant Investment Advisers Inc. acquired a new stake in Novo Nordisk A/S during the 4th quarter worth about $29,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

NVO has been the subject of a number of recent analyst reports. The Goldman Sachs Group reiterated a “neutral” rating and set a $41.00 price target (down from $63.00) on shares of Novo Nordisk A/S in a report on Monday, March 2nd. Zacks Research upgraded Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 10th. Citigroup reiterated a “neutral” rating on shares of Novo Nordisk A/S in a report on Tuesday, May 12th. Deutsche Bank Aktiengesellschaft downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Monday, February 23rd. Finally, Kepler Capital Markets downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Tuesday, February 24th. Four research analysts have rated the stock with a Buy rating, eighteen have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $65.56.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: The U.K. Medicines and Healthcare products Regulatory Agency approved Novo Nordisk’s Wegovy pill, making it the first daily GLP-1 weight-loss tablet cleared in the country and opening another major market for the company’s obesity franchise. UK approves Novo weight-loss pill to edge open European market
• Positive Sentiment: Multiple reports highlighted that the approval could strengthen Novo Nordisk’s competitive position versus Eli Lilly by expanding access to an oral alternative to injectable obesity treatments. Novo Nordisk’s Wegovy Weight Loss Pill Approved in the U.K.
• Positive Sentiment: Analyst-style and market commentary noted that Novo Nordisk’s obesity pipeline remains a key growth driver, with recent Phase 3 data for CagriSem adding to enthusiasm around its longer-term GLP-1 strategy. Novo Nordisk (NVO): Top 10 Large Cap Value Stocks to Buy Now
• Neutral Sentiment: Market wrap articles showed NVO outperforming the broader market in recent trading, reflecting renewed investor interest after the regulatory win. Novo Nordisk (NVO) Outpaces Stock Market Gains: What You Should Know
• Negative Sentiment: Novo Nordisk also disclosed a cybersecurity incident involving unauthorized access to internal IT systems and possible copying of non-public data, which could weigh on sentiment if the breach proves material. Novo Nordisk hit by cyber incident, probes data breach
• Negative Sentiment: A Reuters report said some U.S. employers may drop coverage of GLP-1 obesity drugs in 2027, a potential headwind for future demand growth across the category, including Wegovy. Some US employers to drop coverage of GLP-1 obesity drugs in 2027 as use increases

Novo Nordisk A/S Price Performance

NVO stock opened at $43.98 on Friday. The stock has a market capitalization of $196.37 billion, a PE ratio of 10.32, a price-to-earnings-growth ratio of 3.83 and a beta of 0.78. The company’s 50-day moving average is $42.13 and its 200-day moving average is $46.01. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56. Novo Nordisk A/S has a 1 year low of $35.12 and a 1 year high of $81.44.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Tuesday, March 31st. The company reported $1.03 earnings per share (EPS) for the quarter. The company had revenue of $10.85 billion for the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. Equities research analysts expect that Novo Nordisk A/S will post 3.45 EPS for the current fiscal year.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.